revotar Pages on BioPortfolio:

Biotechnology News MVC PLUS Search
Revotar closes 5.3 million EUR Series A financing round Revotar Biopharmaceuticals AG today announced the successful closing of its Series A
financing round ...
http://www.bioportfolio.co.uk/MVC%20PLUS-news.htm...

BioPortfolio - REVOTAR Biopharmaceuticals AG - Profile
View the current REVOTAR Biopharmaceuticals AG Page on BioPortfolio.com ... Revotar Biopharmaceuticals AG is a privately owned, independent German ...
http://www.bioportfolio.com/biocorporate/29226-REVOTAR+Bioph...

Biotechnology News Phase Trial Clinical Search
Revotar Biopharmaceuticals AG today announced preclinical data from a dermal toxicity study demonstrating that topical administration of Bimosiamose cream
...
http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?DB=ne...

BioPortfolio - bimosiamose
Revotar reports positive Phase I data in psoriasis with its Bimosiamose 5% Cream . ... BioPortfolio - REVOTAR Biopharmaceuticals AG - Profile ...
http://www.bioportfolio.com/search/bimosiamose.html...

Biotechnology and Pharmaceutical Industry Search Find Companies ...
Revotar reports positive Phase I data in psoriasis with its Bimosiamose 5% Cream ... Revotar Reports Positive Phase I Data in Psoriasis with its Bimosiamose ...
http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=e...

BioPortfolio - ratiograstim
BioPortfolio - revotar 2008 Summary of Positive Opinion for Ratiograstim, ... BioPortfolio - REVOTAR Biopharmaceuticals BioPortfolio - ratiograstim ...
http://www.bioportfolio.com/search/ratiograstim.html...

Biotechnology and Pharmaceutical Industry Search Find Companies ...
Revotar Reports Positive Preclinical Data From a 4-month Dermal Toxicity Study. Pharma Live: similar ... UAE lags in care for Rheumatoid Arthritis patients ...
http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=e...

BioPortfolio - Rentschler Biotechnologie GmbH management
Rentschler Biotechnologie GmbH & Co. responsif GmbH · RESprotect GmbH · Revotar Biopharmaceuticals AG · Rheumazentrum Ruhrgebiet . ...
http://www.bioportfolio.com/search/Rentschler_Biotechnologie...

Biotechnology and Pharmaceutical Industry Search Find Companies ...
Revotar Reports Positive Preclinical Data From a 4-month Dermal Toxicity Study. Pharma Live: similar ... Efficacy and Safety of Golimumab Treatment ...
http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=e...

Results from other life science and pharmaceutical sites:

Revotar Biopharmaceuticals Closes 5.3 Million EUR Series A ...
23 Sep 2008 ... HENNIGSDORF/BERLIN, GERMANY, Monday, September 22, 2008 – Revotar Biopharmaceuticals AG today announced the successful closing of its Series ...
http://www.biospace.com/news_story.aspx?NewsEntityId=110449...

BioSpace - Revotar Biopharmaceuticals News, Search Jobs, Events
Revotar Biopharmaceuticals Granted Orphan Drug Designation By The European Medicines Agency For Bimosiamose Disodium To Treat Patients Suffering From Acute
...
http://www.biospace.com/company_profile.aspx?CompanyId=39600...

Revotar Biopharmaceuticals Reports Positive Phase I Data In ...
BERLIN/Hennigsdorf (Germany), October 13, 2008– Revotar Biopharmaceuticals AG today announced data from a Phase I study demonstrating that the topical ...
http://www.biospace.com/news_story.aspx?NewsEntityId=112851...

BioSpace - Print News Article
Revotar Biopharmaceuticals Closes 5.3 Million EUR Series A Financing Round ... Revotar managed to raise more than 8 million EUR since August 2007. ...
http://www.biospace.com/news_print.aspx?NewsEntityId=110449...

{1} Granted Orphan Drug Designation By The European Medicines ...
Revotar Biopharmaceuticals AG is located in Hennigsdorf, ... To learn more about Revotar Biopharmaceuticals AG please visit our web site: www.revotar-ag.de ...
http://www.biospace.com/news_story.aspx?NewsEntityId=2038622...

ENCYSIVE PHARMACEUTICALS
Revotar Biopharmaceuticals AG, a majority owned affiliate of Encysive, ... Revotar is conducting the clinical trials for both indications in Europe. ...
http://www.encysive.com/about_portfolio.html...

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.